Moxifloxacin in the treatment of skin and skin structure infections.

Moxifloxacin in the treatment of skin and skin structure infections. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Moxifloxacin in the treatment of skin and skin structure infections. Abstract Text:

David Rp Guay,

Moxifloxacin is a recent addition to the fluoroquinolone class, differing from ciprofloxacin and other older agents in having much better in vitro activity against Gram-positive aerobes while retaining potent activity against Gram-negative aerobes. It is also active against the pathogens of human and animal bite wounds and those species of atypical mycobacteria associated with dermatologic infections. Its activity against anaerobes is quite variable. Moxifloxacin penetrates well into inflammatory blister fluid and muscle and subcutaneous adipose tissues. Moxifloxacin should thus be a reasonable option for the treatment of skin and skin structure infections (SSSIs). In 3 randomized controlled trials (RCTs), oral moxifloxacin was as effective as cephalexin in the treatment of uncomplicated SSSIs in adults while in 2 RCTs, intravenous/oral moxifloxacin was as effective as intravenous/oral beta-lactam/beta-lactamase inhibitor therapy in the treatment of complicated SSSIs in adults. Moxifloxacin does not inhibit cytochrome P450 enzymes and thus interact with warfarin or methylxanthines. However, multivalent cations can reduce its oral bioavailability substantially. Dosage adjustment is not required in the presence of renal or hepatic impairment. The clinical relevance of its electrophysiologic effects (QT(c) prolongation) remains unresolved.

Moxifloxacin in the treatment of skin and skin structure infections. Publishing Authors By Initials

DR Guay,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Moxifloxacin in the treatment of skin and skin structure infections. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Therapeutics and clinical risk management

VOLUME: 2

Page Numbers: 417-34

Journal Abbreviation:

ISSN: 1176-6336

DAY: 24

MONTH: Dec

YEAR: 2006

Moxifloxacin in the treatment of skin and skin structure infections. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101253281

Moxifloxacin in the treatment of skin and skin structure infections. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Moxifloxacin in the treatment of skin and skin structure infections. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Moxifloxacin in the treatment of skin and skin structure infections.

AFFILIATION: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota Minneapolis, MN, USA.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ther Clin Risk Manag

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Moxifloxacin in the treatment of skin and skin structure infections Related Publications

• A scripted activity study of the impact of protective advice on personal exposure to ultra-fine and fine particulate matter and volatile organic compounds.
• Acute nicotine effects on sexual function in men.
• Adaptive control for a class of second-order nonlinear systems with unknown input nonlinearities.
• Adverse consequences of capsaicin exposure in health care workers.
• Are there alternatives to the use of quinine to treat nocturnal leg cramps?
• Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors.
• Contemporary management of uncomplicated urinary tract infections.
• First, do no harm: balancing the risks and benefits of regional anesthesia in patients with underlying neurological disease/Prudence est mere de surete: evaluer le ratio benefice/risque de l'anesthesie regionale chez les patients porteurs de pathologie ne
• Geriatric pharmacotherapy updates.
• Geriatric pharmacotherapy updates.
• Geriatric pharmacotherapy updates.
• Geriatric pharmacotherapy updates.
• Global experiences with vardenafil in men with erectile dysfunction and underlying conditions.
• High optical transparency and good adhesion of diamond films deposited on fused silica windows with a surface-wave sustained plasma.
• Moxifloxacin in the treatment of skin and skin structure infections.
• Newer antiepileptic drugs in the management of agitation/aggression in patients with dementia or developmental disability.
• Pneumococcal polysaccharide revaccination: immunoglobulin g seroconversion, persistence, and safety in frail, chronically ill older subjects.
• Radiographic assessment of asymmetry of the mandible.
• Regional anesthesia for carotid surgery.
• The role dentists can play in mass casualty and disaster events.
• Topical clindamycin in the management of acne vulgaris.
• Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence.
• Update on clindamycin in the management of bacterial, fungal and protozoal infections.
• [Impact of moment of disclosure of a sexual assault on certain affective and relational aspects of adult victims.]
• [Not Available.]
• [Not Available.]
• [Taenia infestation: new method of treatment.]
• [The social worker and family caregivers.]